Rapid post-fire re-assembly of species-rich bryophyte communities in Afroalpine heathlands

Questions In some fire-prone ecosystems, bryophytes play a crucial role by providing the surface fuel that controls the fire return interval. Afroalpine heathlands are such an ecosystem, yet almost nothing is known about the bryophytes in this system. We do not know the level of species richness, or if there is a successive accumulation of species over time, or if some species are adapted to specific phases along the successional gradient, for example early-successional species sensitive to competition. Location Afroalpine heathlands in Ethiopia. Methods We made an inventory of all bryophytes in 48 plots of 5 m × 5 m, distributed along a chronosequence from 1 to 25 years post fire. The heathlands are located between 3500 m and 3800 m a.s.l. and are managed by traditional pasture burning with fire intervals of 8–20 years. Results We found in total 111 taxa of bryophytes. Post-fire mortality was almost 100%. The youngest plots had only a few cosmopolitan species often found after fire. Initially, species richness increased monotonically while starting to level off around 15 years after fire, when many plots had around 30 species and a high cover of Breutelia diffracta, which is a key ground-living species, important as surface fuel. Most species were found with sporophytes, a pattern even stronger for the most frequent species. Conclusions Interestingly, bryophyte diversity is already remarkably high by only 15 years after total eradication. The relatively slow accumulation of species in the first years after fire suggests that dispersal in space, and not time, is the major mechanism by which sites regain their diversity (i.e. spore banks play a smaller role than colonization of wind-borne spores). This indicates that the high species richness is built up through colonization from surrounding heathlands, and perhaps also from higher-altitude alpine grasslands and lower-altitude forests, and that the bryophyte diversity in this system is maintained by the traditional fire and grazing management

Defining the Critical Hurdles in Cancer Immunotherapy

ABSTRACT: Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators, others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet be overcome to improve outcomes of patients with cancer